$5.40 +0.15 (2.86%) ChemoCentryx Inc - NASDAQ

Sep. 27, 2016 | 09:40 AM
Last Trade: 5.40
Trade Time: Sep 27 09:40 AM Eastern Daylight Time
Change: +0.15 (2.86%)
Prev Close: 5.25
Open: 5.28
Bid: 5.40
Ask: 5.41
  1. No results found.
  1. ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168

    Benzinga | Jan. 6, 2016 | 07:00AM EST
  2. Wednesday's After-Hours Movers: 10 Stocks To Watch

    Benzinga | Sep. 24, 2015 | 08:10AM EST
  3. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

    Benzinga | Jan. 13, 2015 | 10:58AM EST
  4. Biggest Gainers From Friday, December 12, 2014

    Benzinga | Dec. 12, 2014 | 16:31PM EST
  5. Mid-Morning Market Update: Markets Open Lower; Adobe Earnings Top Expectations

    Benzinga | Dec. 12, 2014 | 11:34AM EST
  6. ChemoCentryx Up 70%, Lead Drug Meets Phase II Objective

    Benzinga | Dec. 12, 2014 | 10:37AM EST
  7. Morning Market Movers

    Benzinga | Dec. 12, 2014 | 09:42AM EST
  8. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 12, 2014 | 08:07AM EST
  9. ChemoCentryx Reports Positive Phase II Diabetic

    Benzinga | Dec. 12, 2014 | 06:33AM EST
  10. Three Attractively Priced Small Cap Biotech Stocks

    GuruFocus | Nov. 5, 2014 | 12:45PM EST
  11. ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease

    Benzinga | Oct. 20, 2014 | 08:32AM EST
  12. ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology

    Benzinga | Mar. 27, 2014 | 08:31AM EST
  13. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 4, 2013 | 08:11AM EST
  14. ChemoCentryx Will Regain Global Rights for Vercirnon from Glaxo, Will Assess If Drug Maintains Remission in Crohn's Disease

    Benzinga | Sep. 18, 2013 | 08:39AM EST
  15. Morning Market Losers

    Benzinga | Sep. 10, 2013 | 10:24AM EST
Trading Center